MAY 09, 2017 10:00 AM PDT

WEBINAR: Querying Cytokine-Signaling Networks in Myeloproliferative Neoplasms

Sponsored by: Fluidigm
Speakers

Abstract

DATE: May 9th, 2017
TIME: 10:00AM PDT, 1:00PM ET

Myeloproliferative neoplasms including myelofibrosis (MF) are characterized by anemia, splenomegaly, bone marrow fibrosis and inflammatory cytokine production. JAK2 inhibition with ruxolitinib improves symptoms and lowers circulating plasma cytokine levels but does not ameliorate anemia, fibrosis or malignant clonal burden. The goal of this study is to better define the relationship between dysregulated cytokines and downstream signaling in MF and to determine how these pathways can be effectively manipulated for therapeutic benefit.

To interrogate altered signaling in MF, we have employed mass cytometry, a novel technology that enables the quantitative analysis of more than 40 parameters at the single-cell level. We identified NF-kB pathway hyperactivation distributed across multiple hematopoietic cell populations, including T cells. Plasma TNFα levels were elevated in these subjects, suggesting that excessive production of TNFα may lead to broad activation of NF-κB in a non-cell-autonomous fashion.

To further elucidate the etiology of systemic NF-κB hyperactivation, we extended our mass cytometry approach to study the cellular distribution of cytokine production in MF. Intracellular levels of several cytokines (including TNFα) were constitutively elevated in MF subjects compared to healthy controls. Supranormal cytokine expression was accentuated by stimulation with PMA/ionomycin or TLR ligands R-848 or Pam3CSK4. PMA/ionomycin increased production of TNFα from MF CD34+ cells and CD33+ immature myeloid cells.

These findings imply that multiple cell populations in MF overexpress inflammatory cytokines and are hypersensitive to potentiating stimuli. Future experiments will identify signaling effects of multiple elevated cytokines, which may underlie MF features that persist despite JAK2 inhibitor therapy.

Jennifer Frahm, PhD, of Fluidigm will give a brief overview of mass cytometry, the high-parameter, single-cell analysis technology used by Dr. Oh in his research. 

Learning Objectives:

  •  Why current treatments for myeloproliferative neoplasms fall short and why additional research is needed
  •  How high-dimensional analysis with mass cytometry can identify signaling pathway abnormalities in  hematopoietic cell subsets in myelofibrosis
  •  How mass cytometry can delineate the cellular sources of aberrant cytokine production in  myelofibrosis

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


Show Resources
You May Also Like
MAY 11, 2021 10:00 AM PDT
C.E. CREDITS
MAY 11, 2021 10:00 AM PDT
Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
SEP 14, 2021 7:00 AM PDT
C.E. CREDITS
SEP 14, 2021 7:00 AM PDT
Date: September 14, 2021 Time: 7am PDT, 10am EDT, 4pm CEST A conventional thermal cycler has long been a commodity product in the lab and end-point PCR techniques can be completed almost wit...
JUN 09, 2021 7:00 AM PDT
C.E. CREDITS
JUN 09, 2021 7:00 AM PDT
Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
APR 01, 2021 8:00 AM PDT
C.E. CREDITS
APR 01, 2021 8:00 AM PDT
Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
MAR 16, 2021 10:00 AM PDT
C.E. CREDITS
MAR 16, 2021 10:00 AM PDT
Date: March 16, 2021 Time: 10:00am (PST) Scientific progress and breakthroughs today are often too expensive for most institutions to acquire. Each year, the National Institutes of Health (N...
MAY 18, 2021 8:00 AM PDT
C.E. CREDITS
MAY 18, 2021 8:00 AM PDT
Date: May 18, 2021 Time: 8:00am (PST) The global pandemic has caused an increased focus and scrutiny on molecular diagnostic assay development, resulting in a need for assays that provide qu...
MAY 09, 2017 10:00 AM PDT

WEBINAR: Querying Cytokine-Signaling Networks in Myeloproliferative Neoplasms

Sponsored by: Fluidigm

Specialty

Cancer Research

Immunology

Molecular Biology

Cancer Diagnostics

Biomarkers

Cell Biology

Cancer Therapeutics

Biotechnology

Clinical Diagnostics

Laboratory Testing

Microbiology

Clinical Research

Genetics

Infectious Disease

Molecular Diagnostics

Geography

North America69%

Europe13%

Asia9%

Africa4%

South America3%

Registration Source

Website Visitors100%

Job Title

Student14%

Research Scientist14%

Executive13%

Scientist10%

Educator/Faculty9%

Post Doc8%

Medical Laboratory Technician7%

Medical Doctor/Specialist7%

Facility/Department Manager6%

Lab Management4%

Clinical Laboratory Scientist3%

Marketing/Sales2%

Biologist2%

Chemist1%

Organization

Academic Institution16%

Biotech Company7%

Clinical Laboratory6%

Research Institute5%

Hospital5%

Life Science Company4%

Pharmaceutical Company4%

Ambulatory Care2%

Medical Center1%

Medical School1%

Government1%

Consultant1%

Private Practice1%

Media1%

Other4%


Show Resources
Loading Comments...
Show Resources